Remarkably, functional alterations of Lrp4 using blocking antibodies or specific mutations, both observed in human patients, induce Myasthenia gravis and a form of Congenital myasthenic syndrome, respectively [52,53]. Here, LRP4 is linked to congenital myasthenic syndrome.